

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO									
<div style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i></div>						<i>Complete if Known</i>			
						Application Number		10/585,695	
						Filing Date		August 20, 2008	
						First Named Inventor		SOREQ Hermona et al	
						Art Unit		1651	
						Examiner Name		Not Yet Assigned	
						Attorney Docket Number		30394	
Sheet	1	of	2						
U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Document Number	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		Number-Kind Code ² (if known)							
	1	2004/0208845	21-Oct-2004	Michal et al.					
	2	2006/0083721	20-Apr-2006	Cohen et al.					
	3	5,614,204	25-Mar-1997	Cochrum					
	4	5,667,778	16-Sep-1997	Atala					
FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		Country Code ³ Number ⁴ : Kind Code ⁵ (if known)							
	5	WO 2005/066337	21-Jul-2005	Soreq et al.					
Examiner Signature					Date Considered				

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/585,695
				Filing Date	August 20, 2008
				First Named Inventor	SOREQ Hermona et al
				Group Art Unit	1651
				Examiner Name	Not Yet Assigned
Sheet	2	Of	2	Attorney Docket Number	30394
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	6	Communication Pursuant to Article 94(3) EPC Dated 05 November 2008 From the European Patent Office Re.: Application No. 05703071.0.			
	7	Communication Pursuant to Article 94(3) EPC Dated 05 November 2008 From the European Patent Office Re: Application EP05703071.0			
	8	Communication Pursuant to Article 96(2) EPC Dated 09 October 2007 From the European Patent Office Re: Application No. EP 047310941			
	9	Communication Pursuant to Article 96(2) EPC Dated 10 March 2006 From the European Patent Office Re.: Application No. 04731094.1.			
	10	Examiner's Report Dated 17 October 2008 From the Australian Government, IP Australia Re.: Application No. 2005211584.			
	11	Examiner's Report Dated 21 November 2007 From the Australian Government, IP Australia Re.: Application No. 2005211584.			
	12	International Preliminary Report on Patentability Dated 10 July 2006 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/000028.			
	13	International Search Report Dated 16 September 2004 From the International Searching Authority Re.: Application No. PCT/IL2004/000371.			
	14	International Search Report Dated 22 September 2005 From the International Searching Authority Re.: Application No. PCT/IL05/000028.			
	15	Becker et al. "Calcium Alginate Gel: A Biocompatible and Mechanically Stable Polymer for Endovascular Embolization", Journal of Biomedical Materials Research, 54: 76-86, 2001.			
	16	Becker et al. "Flow Properties of Liquid Calcium Alginate Polymer Injected Through Medical Microcatheters for Endovascular Embolization", Journal of Biomedical Materials Research, 61: 533-540, 2002.			
	17	Cohen et al. "A Novel In Situ-Forming Ophthalmic Drug Delivery System From Alginates Undergoing Gelation in the Eye", Journal of Controlled Release, 44: 201-208, 1997.			
	18	Güngör et al "Investigations On Mefenamic Acid Sustained Release Tablets With Water-Insoluble Gel", Il Farmaco 58:397-401 (2003)			
	19	Gutowska et al "Injectable Gels For Tissue Engineering", The Anatomical Record 263:342-349 (2001)			
	20	Shapiro et al "Efficacies Of Vaccines Containing Alginate Adjuvant", J. Appl. Bact. 30(2):304-311 (1967)			
	21	Shapiro et al "Novel Alginate Sponges For Cell Culture And Transplantation", Biomaterials 18(8):583-590 (1997)			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450